EpiVax Oncology, a precision cancer immunotherapy company, is developing mutanome-directed, neo-epitope personalized immunotherapies. EpiVax Oncology’s immunotherapies are customized and specifically designed for each patient’s tumors, leveraging advances in next generation sequencing and computational immunology.
Our superior neo-epitope selection process is based on Ancer™, advanced in-silico machine-learning algorith...
EpiVax Oncology, a precision cancer immunotherapy company, is developing mutanome-directed, neo-epitope personalized immunotherapies. EpiVax Oncology’s immunotherapies are customized and specifically designed for each patient’s tumors, leveraging advances in next generation sequencing and computational immunology.
Our superior neo-epitope selection process is based on Ancer™, advanced in-silico machine-learning algorithms, exclusively licensed to EpiVax Oncology by EpiVax.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.